Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
claudin-4 small interfering RNA
- Development stage
- Preclinical
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Oral, Topical
01
Overview
Claudin-4 (CLDN4) small interfering RNA (siRNA) is an RNA interference-based therapeutic approach designed to silence the expression of the CLDN4 gene. CLDN4 is a tight junction protein frequently overexpressed in various cancers, including bladder urothelial carcinoma (BUC), where it correlates with cancer progression, stemness, and drug resistance. By targeting CLDN4 mRNA for degradation, the siRNA reduces the levels of both tight-junction-integrated and unintegrated CLDN4 protein. Research indicates that reducing CLDN4 levels can inhibit cell proliferation, decrease metastatic potential, and sensitize cancer cells to apoptosis, potentially through the modulation of FAK phosphorylation and integrin β1 signaling. While primarily used as a research tool to investigate the oncogenic mechanisms of CLDN4, it represents a potential therapeutic strategy for cancers overexpressing this protein.
- Other names
- CLDN4 siRNACLDN-4 siRNACLDN 4 siRNAsiCLDN4siCLDN-4siCLDN 4cldn4 small interfering RNAcldn-4 small interfering RNAcldn 4 small interfering RNA
02
Targets
CLDN4 (Claudin-4)
Beyond the preview
Go deeper on claudin-4 small interfering RNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on claudin-4 small interfering RNA.